Any current/future new fundraising through debt or equity?

No specific information on new fundraising through debt or equity mentioned for the current or immediate future. Gross debt may slightly increase in FY '27 due to capex plans. Capex guidance increased from INR 1,000 crore annually to INR 1,500 crore and projected INR 3,000 crore over next 2 years, mainly growth capex with visibility on projects/customers. Debt-to-EBITDA ratio expected to remain stable or improve slightly despite higher gross debt. Strong internal cash flows support capex and debt levels. No mention of equity fundraising or new debt issuance plans.

Any current/future capex/capital investment/strategic investment?

Laurus Labs is executing a new greenfield capex of 500 acres in Atchutapuram; specific timeline details to be shared next quarter. Capex guidance has increased from INR 1,000 crores annually to approximately INR 1,500 crores annually, with an expectation to spend around INR 3,000 crores over the next two years. Over 75% of recent investments focus on expansion of CDMO and CMO capabilities, with the remainder allocated to infrastructure like Effluent Treatment Plant (ETP) and maintenance. Significant capex is dedicated to building large peptide manufacturing capacity; precise figures are

Future growth expectations in sales/revenue/volumes?

Laurus Labs expects continued strong growth next year with the order book well in place (Soumya Chava). CDMO business is growing robustly with several late-stage clinical programs; some are anticipated to commercialize in FY '27 (Krishna Chaitanya Chava). CDMO revenues are targeted to reach 50% of overall sales by 2030 (Satyanarayana Chava). ARV sales volume is expected to remain roughly constant (~INR 2,800 crores), but its percentage contribution to revenue will decline as CDMO grows (Satyanarayana Chava). Expansion plans include significant capex (~INR 1,500 crores annually, increas

Future growth expectations in earnings/operating earnings/profits/EPS?

Laurus Labs expects continued strong growth, particularly in the CDMO segment, with CDMO revenues projected to reach 50% of overall sales by FY2030. EBITDA margins improved to 26.8% in FY '26 and are expected to be maintained or improved in FY '27, with Q4 EBITDA margin reaching nearly 29%. Operational leverage is anticipated to play a bigger role over the next 1-2 years as capacities expand, supporting margin improvement. Growth in CDMO is expected to be steady, driven by a robust pipeline and multiple commercial products, mitigating concentration and destocking risks. Affordable Medicines se

Current/ Expected Orderbook/ Pending Orders?

Soumya Chava mentioned that the order book for the next year is "pretty much in place," indicating strong visibility and continuity of orders. Krishna Chaitanya Chava stated that while specific numbers are not disclosed, they have a robust pipeline of CDMO programs, including several late-stage and clinical programs with expected commercialization. The company is confident about the growing order book in the CDMO segment and anticipates growth in FY '27, supported by these pipelines and ongoing projects. They are cautious in giving specific quantitative visibility due to the clinical nature of

IN US

Sale is live|00:00:00left today

Laurus Labs LtdQ1 FY26Pharmaceuticals & Biotechnology

Laurus Labs Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,450P/E: 80.4Market Cap: ₹71.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Laurus Labs expects continued strong growth next year with the order book well in place (Soumya Chava).
→CDMO business is growing robustly with several late-stage clinical programs; some are anticipated to commercialize in FY '27 (Krishna Chaitanya Chava).
→CDMO revenues are targeted to reach 50% of overall sales by 2030 (Satyanarayana Chava).
→ARV sales volume is expected to remain roughly constant (~INR 2,800 crores), but its percentage contribution to revenue will decline as CDMO grows (Satyanarayana Chava).
→Expansion plans include significant capex (~INR 1,500 crores annually, increased from INR 1,000 crores) focused on growth and capacity tied to confirmed customer demand (Satyanarayana Chava).
→Affordable Medicines division grew 18% in FY '26, with steady outlook driven by volume increases and new product launches (Soumya Chava).
→The fermentation capacity and formulation expansions aim to support volume growth across segments.

Margin guidance

Category 3

→Laurus Labs expects continued strong growth, particularly in the CDMO segment, with CDMO revenues projected to reach 50% of overall sales by FY2030.
→EBITDA margins improved to 26.8% in FY '26 and are expected to be maintained or improved in FY '27, with Q4 EBITDA margin reaching nearly 29%.
→Operational leverage is anticipated to play a bigger role over the next 1-2 years as capacities expand, supporting margin improvement.
→Growth in CDMO is expected to be steady, driven by a robust pipeline and multiple commercial products, mitigating concentration and destocking risks.
→Affordable Medicines segment grew 18% in FY '26 and is expected to maintain steady growth.
→Profit after tax surged 148% in FY '26, with continuing focus on R&D and capacity expansion supporting future earnings growth.
→Return ratios and margins benefit from visible growth capex backed by secured orders, signaling improved efficiency and profitability.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No specific information on new fundraising through debt or equity mentioned for the current or immediate future.
→Gross debt may slightly increase in FY '27 due to capex plans.
→Capex guidance increased from INR 1,000 crore annually to INR 1,500 crore and projected INR 3,000 crore over next 2 years, mainly growth capex with visibility on projects/customers.
→Debt-to-EBITDA ratio expected to remain stable or improve slightly despite higher gross debt.
→Strong internal cash flows support capex and debt levels.
→No mention of equity fundraising or new debt issuance plans.

Order book

Yes

→Soumya Chava mentioned that the order book for the next year is "pretty much in place," indicating strong visibility and continuity of orders.
→Krishna Chaitanya Chava stated that while specific numbers are not disclosed, they have a robust pipeline of CDMO programs, including several late-stage and clinical programs with expected commercialization.
→The company is confident about the growing order book in the CDMO segment and anticipates growth in FY '27, supported by these pipelines and ongoing projects.
→They are cautious in giving specific quantitative visibility due to the clinical nature of products but express confidence in continued growth and commercialization.
→Current capacities, including fermentation and peptide production, are being expanded to meet demand, reflecting strong order inflow and pipeline strength.

Capex plans

Yes

→Laurus Labs is executing a new greenfield capex of 500 acres in Atchutapuram; specific timeline details to be shared next quarter.
→Capex guidance has increased from INR 1,000 crores annually to approximately INR 1,500 crores annually, with an expectation to spend around INR 3,000 crores over the next two years.
→Over 75% of recent investments focus on expansion of CDMO and CMO capabilities, with the remainder allocated to infrastructure like Effluent Treatment Plant (ETP) and maintenance.
→Significant capex is dedicated to building large peptide manufacturing capacity; precise figures are not disclosed but described as "large."
→New formulation facility commissioning in June includes tertiary packaging capacity aligned to a large existing CMO contract (3 billion tablets).
→Vizag fermentation facility is expanding capacity in phases, aiming for up to 1 million liters capacity.
→Capex projects have visibility with confirmed product and customer demand, minimizing speculative investments.

How does Laurus Labs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Laurus Labs Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Laurus Labs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio